Through the PrecivityAD® test, your healthcare provider can now offer to you an easy to administer blood test that enables precise and sensitive measurements to aid in the diagnostic evaluation of changes in thinking or memory.
Overview of the PrecivityAD® Test for Individuals
Summary of Test and Intended Use Population
The test aims to help healthcare providers better determine the presence or absence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease. These measurements are made from a single blood sample.
Mass spectrometry, a highly precise technique, is used to quantify the blood ratio of amyloid beta 42 and 40 peptides (the Aβ42/Aβ40 ratio) and to characterize the patient’s Apolipoprotein E proteotype (equivalent to ApoE genotype) profile—a risk factor for Alzheimer’s disease.
Only your healthcare provider can order the PrecivityAD® blood test for you.
Who should have the PrecivityAD® test?
Talk to your healthcare provider if you are experiencing issues with your memory and thinking. Your healthcare provider can determine if the PrecivityAD® test is right for you.
The PrecivityAD® Test Results and Interpretation report includes:
The Amyloid Probability Score (APS) represents the estimated likelihood from 0 (low likelihood) to 100 (high likelihood) that the patient will be amyloid positive on amyloid PET imaging based on his or her Aβ42/40 ratio, age, and ApoE profile. A positive amyloid PET scan is consistent with presence of amyloid plaques and an Alzheimer's disease diagnosis.
In addition to APS, the test report includes the patient’s Aβ 42/40 ratio and ApoE genotype results. Although each of these parameters can individually assess amyloid risk, their use in combination with the patient’s age to calculate the APS is superior, and therefore is the most important result.
The report provides a visual range of Low, Intermediate and High likelihood of amyloid plaques in the brain. In addition, the report provides an interpretation of the PrecivityAD® test, background and methods.
Talking to Your Healthcare Provider
This printable flyer has more information on the PrecivityAD® test, which is only available by a healthcare provider’s order. Talk to your healthcare provider to see if the PrecivityAD® test is right for you.
How it Works
Step 1
Your healthcare provider
orders the
PrecivityAD®
test and
schedules a
blood draw
appointment
Step 2
Your blood sample is
sent to the C₂N
laboratory for
analysis by mass
spectrometry
Step 3
Your healthcare provider
receives the
PrecivityAD®
test report and
discusses
results with you
The Benefits of an Early Diagnosis
Your decision to obtain a test for memory issues is a very personal decision made best in consultation with your family and healthcare provider. There are many advantages of receiving an early diagnosis of Alzheimer’s disease. Share this information with family, friends and your healthcare provider.
What it Costs
The PrecivityAD® test is new and is not currently covered by private insurance companies, Medicare or Medicaid. Patients are responsible for paying for the test out-of-pocket. A financial assistance program is available for those patients who medically and financially qualify. Six-month, interest-free financing is also available to facilitate access to the PrecivityAD® test for patients. C₂N is currently working to establish reimbursement for the PrecivityAD® test.
